题名

降血糖藥物之心血管結果試驗：系統回顧及統合分析

并列篇名

Cardiovascular Outcome Trials of Antidiabetic Agents: A Systematic Review and Meta-analysis

DOI

10.3966/168232812020093003004

作者

蔡崇煌(Chung-Huang Tsai)；張惠雯(Hui-Wen Chang)；曾立年(Li-Nien Tseng)；顏啟華(Chi-Hua Yen)；江韶岳(Shao-Yueh Chiang)

关键词

心血管結果試驗 ； 主要不良心血管事件 ； 腦中風 ； CVOTs ； MACE ； stroke

期刊名称

台灣家庭醫學雜誌

卷期/出版年月

30卷3期（2020 / 09 / 01）

页次

153 - 168

内容语文

繁體中文
中文摘要

目的：美國食品藥物管理局建議所有2008年後新上市的降血糖藥物，需進行心血管結果試驗（CVOTs），本研究目的為探討CVOTs，並做一系統回顧及統合分析。方法：以EndNote X9，關鍵詞為“Cardiovascular Outcome(s) Trial(s)＂ OR＂CVOT(s)＂，AND＂Diabetes＂，搜尋2008/1/1至2019/11/30之PubMed medline、Cochrane及Web of Science等資料庫，再由此分別找出降血糖藥物之CVOTs。使用Comprehensive Meta-Analysis 3軟體計算風險比（HR）、95%信賴區間（CI）及權重，並用MS-Excel 2019畫森林圖（forest plot），若誤差線未交叉到1.0無效線，表示達統計學上顯著的差異。結果：共收錄24個研究，其中昇糖素類似胜肽1-受體促效劑（GLP1-RA）可顯著下降12% 3項（3-point, 3-P）主要不良心血管事件（major adverse cardiovascular events, MACE）（HR 0.88, 95% CI 0.82- 0.94），其中SUSTAIN 6（Semaglutide）（0.61, 0.38-0.99）及REWIND（Dulaglutide）（0.76, 0.61-0.95）可顯著下降腦中風風險。鈉－葡萄糖協同轉運蛋白2抑制劑（SGLT2i）可顯著下降11% 3-P MACE（0.89,0.83-0.96），因心衰竭住院（HHF）顯著下降31%（0.69, 0.61-0.79），腎臟疾病進展組合亦有極顯著下降45%（0.55, 0.48-0.64）。二肽基肽酶4抑製劑（Dipeptidyl peptidase 4 inhibitor）為中性結果（0.99, 0.94-1.05），其中CARMELINA（Linagliptin）發現可顯著減少白蛋白尿的進展（0.86, 0.78-0.95），但SAVOR TIMI53（Saxagliptin）因心衰竭住院顯著上昇了27%（1.27, 1.07-1.51）。結論：SGLT2i及GLP1-RA可下降3-P MACE，再者SGLT2i對心衰竭及腎臟亦有保護作用，部份GLP1-RA發現可下降腦中風風險，因此歐美及國內目前對第2型糖尿病治療方針有全新的改變。
英文摘要

Purpose: The US Food and Drug Administration recommends that cardiovascular outcome trials (CVOTs) should be conducted for all new antidiabetic drugs introduced into the market after 2008. The study thus initiated a systematic review and meta-analysis of the CVOTS of antidiabetic agents. Methods: We searched PubMed, Cochrane and Web of Science in EndNote X9 for trial results published from January 1, 2008 to November 30, 2019, using the keywords: ＂Cardiovascular Outcome(s) Trial(s)＂ OR ＂CVOT(s)＂ AND ＂Diabetes＂ to identify the CVOTs of antidiabetic drugs separately. Comprehensive Meta-Analysis 3 was used to calculate the hazard ratios (HR) with 95% CI and weights, and the forest plots were drawn with MS-Excel 2019 with VBA. Significant difference was indicated if the error bars did not cross the no-effect line 1.0. Results: A total of 24 CVOTs were cited. Overall, Glucagon-like peptide 1-receptor agonist (GLP1-RA) was able to significantly reduce 12% 3-point major adverse cardiovascular events (3-P MACE) (HR 0.88, 0.82- 0.94), while SUSTAIN 6 (0.61, 0.38-0.99) and REWIND (Dulaglutide) (0.76, 0.61-0.95) were found to significantly reduce stroke. SGLT2i was able to significantly reduce 3-P MACE by 11% (HR 0.89, 95% CI 0.83-0.96), hospitalization for heart failure (HHF) by 31% (HR 0.69, 95% CI 0.61-0.79), and renal composite by 45% (0.55, 0.48-0.64). Dipeptidyl peptidase 4 inhibitors showed neutral result (0.99, 0.94-1.05); CARMELINA (Linagliptin) could significantly reduce albuminuria progression (0.86, 0.78-0.95). SAVOR TIMI 53 (Saxagliptin), however, appeared to increase HHF by 27% (1.27, 1.07-1.51). Conclusion: In addition to their ability to reduce 3-P MACE, SGLT2i also reports protective effects on HHF and kidneys and GLP1-RA can reduce the risk of stroke, thus facilitating recent changes in type 2 diabetes treatment in Europe, America and Taiwan.
主题分类 醫藥衛生 > 社會醫學
参考文献
  1. 蔡崇煌,張加憲,王俊堯,曾立年(2019)。SGLT2抑制劑之心血管和腎臟結果試驗及嚴重副作用：統合分析。台灣家醫誌，57-67。
    連結：
  2. Bertsch, T,McKeirnan, K(2018).Itca 650.Clin Diabetes,36,265-267.
  3. Bethel, MA,Green, JB,Milton, J(2015).Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).Diabetes Obes Metab,17,395-402.
  4. Bradburn, MJ,Deeks, JJ,Berlin, JA,Russell Localio, A(2007).Much ado about nothing: a comparison of the performance of metaanalytical methods with rare events.Stat Med,26,53-77.
  5. Cannon, CP,McGuire, DK,Pratley, R(2018).Design and baseline characteristics of the evaluation of ertugliflozin efficacy and safety cardiovascular outcomes trial (VERTIS-CV).Am Heart J,206,11-23.
  6. Cefalu, WT,Kaul, S,Gerstein, HC(2018).Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a diabetes care editors' expert forum.Diabetes Care,41,14-31.
  7. Center for Drug Evaluation and Research. Guidance for Industry Diabetes Mellitus: Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. Available from: https://bit.ly/340RLst. 2008.
  8. Chiasson, JL,Josse, RG,Gomis, R,Hanefeld, M,Karasik, A,Laakso, M(2003).Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.JAMA,290,486-494.
  9. Da Silva, RR(2018).Commentary: The potential role of the dipeptidyl peptidase-4-like activity from the gut microbiota on the host health.Front Microbiol,9,3313.
  10. Davies, MJ,D'Alessio, DA,Fradkin, J(2018).Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetes Care,41,2669-2701.
  11. Di Angelantonio, E,Kaptoge, S,Wormser, D(2015).Association of cardiometabolic multimorbidity with mortality.JAMA,314,52-60.
  12. Dormandy, JA,Charbonnel, B,Eckland, DJ(2005).Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.Lancet,366,1279-1289.
  13. Erdmann, E,Califf, R,Gerstein, HC(2015).Effects of the dual peroxisome proliferator activated receptor activator aleglitazar in patients with type 2 diabetes mellitus or prediabetes.Am Heart J,170,117-1422.
  14. Fadini, GP,Bonora, BM,Mayur, S,Rigato, M,Avogaro, A(2018).Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors.Diabetes Obes Metab,20,740-744.
  15. Fei, Y,Tsoi, MF,Cheung, BMY(2019).Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta analysis.Cardiovasc Diabetol,18,112.
  16. Gantz, I,Chen, M,Suryawanshi, S(2017).A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus.Cardiovasc Diabetol,16,112.
  17. Garg, SK,Peters, AL,Buse, JB,Danne, T(2018).Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: a STICH protocol.Diabetes Technol Ther,20,571-575.
  18. Gerstein, HC,Bosch, J,Dagenais, GR(2012).Basal insulin and cardiovascular and other outcomes in dysglycemia.N Engl J Med,367,319-328.
  19. Gerstein, HC,Colhoun, HM,Dagenais, GR(2019).Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double blind, randomised placebo-controlled trial.Lancet,394,121-130.
  20. Gerstein, HC,Miller, ME,Byington, RP(2008).Effects of intensive glucose lowering in type 2 diabetes.N Engl J Med,358,2545-2459.
  21. Goldenberg, RM,Berard, LD,Cheng, AYY(2016).SGLT2 Inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis.Clin Ther,38,2654-2664.
  22. Hernandez, AF,Green, JB,Janmohamed, S(2018).Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo controlled trial.Lancet,392,1519-1529.
  23. Holman, RR,Bethel, MA,Mentz, RJ(2017).Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes.N Engl J Med,377,1228-1239.
  24. Holman, RR,Chan, JCN,Chan, JCN(2017).Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo controlled trial.Lancet Diabetes Endocrinol,5,877-886.
  25. Holman, RR,Haffner, SM,McMurray, JJ(2010).Effect of nateglinide on the incidence of diabetes and cardiovascular events.N Engl J Med,362,1463-1476.
  26. Home, PD,Pocock, SJ,Beck-Nielsen, H(2009).Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.Lancet,373,2125-2135.
  27. Huff, TA,Lebovitz, HE,Heyman, A,Davis, L(1972).Serial changes in glucose utilization and insulin and growth hormone secretion in acute cerebrovascular disease.Stroke,3,543-552.
  28. Husain, M,Birkenfeld, AL,Donsmark, M(2019).Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes.N Engl J Med,381,841-851.
  29. Inagaki, N,Yang, W,Watada, H(2020).Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial.Diabetol Int,11,129-141.
  30. Kernan, WN,Viscoli, CM,Furie, KL(2016).Pioglitazone after ischemic stroke or transient ischemic attack.N Engl J Med,374,1321-1331.
  31. Lincoff, AM,Tardif, JC,Schwartz, GG(2014).Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.JAMA,311,1515-1525.
  32. Mahaffey, KW,Hafley, G,Dickerson, S(2013).Results of a reevaluation of cardiovascular outcomes in the RECORD trial.Am Heart J,166,240-9 e1.
  33. Marso, SP,Bain, SC,Consoli, A(2016).r outcomes in patients with type 2 diabetes.N Engl J Med,375,1834-1844.
  34. Marso, SP,Daniels, GH,Brown-Frandsen, K(2016).Liraglutide and cardiovascular outcomes in type 2 diabetes.N Engl J Med,375,311-322.
  35. Marso, SP,McGuire, DK,Zinman, B(2017).Efficacy and safety of degludec versus glargine in type 2 diabetes.N Engl J Med,377,723-732.
  36. McMurray, JJV,Solomon, SD,Inzucchi, SE(2019).for the DAPA-HF Trial Committees and Investigators: Dapagliflozin in patients with heart failure and reduced ejection fraction.N Engl J Med,381,1995-2008.
  37. Neal, B,Perkovic, V,Mahaffey, KW(2017).Canagliflozin and cardiovascular and renal events in type 2 diabetes.N Engl J Med,377,644-657.
  38. Nissen, SE,Wolski, K(2007).Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.N Engl J Med,356,2457-2471.
  39. Nissen, SE,Wolski, K(2010).Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.Arch Intern Med,170,1191-1201.
  40. Pfeffer, MA,Claggett, B,Diaz, R(2015).Lixisenatide in patients with type 2 diabetes and acute coronary syndrome.N Engl J Med,373,2247-2257.
  41. Rao Kondapally Seshasai, S,Kaptoge, S,Thompson, A(2011).Diabetes mellitus, fasting glucose, and risk of cause-specific death.N Engl J Med,364,829-841.
  42. Riddle, MC(2019).A verdict for glimepiride: effective and not guilty of cardiovascular harm.Diabetes Care,42,2161-2163.
  43. Rosenstock, J,Buse, JB,Azeem, R(2018).Efficacy and safety of ITCA 650, a novel drug-device GLP-1 receptor agonist, in type 2 diabetes uncontrolled with oral antidiabetes drugs: The FREEDOM-1 Trial.Diabetes Care,41,333-340.
  44. Rosenstock, J,Kahn, SE,Johansen, OE(2019).Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: The CAROLINA Randomized Clinical Trial.JAMA,322,1155-1166.
  45. Rosenstock, J,Perkovic, V,Johansen, OE(2019).Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA Randomized Clinical Trial.JAMA,321,69-79.
  46. Ryan, PB,Buse, JB,Schuemie, MJ(2018).Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE4D).Diabetes Obes Metab,20,2585-2597.
  47. Schernthaner, G,Khunti, K,Lotan, C,Burnier, M,Drexel, H(2017).Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D).Ther Clin Risk Manag,13,1569-1576.
  48. Schnell, O,Ryden, L,Standl, E,Ceriello, A(2016).Current perspectives on cardiovascular outcome trials in diabetes.Cardiovasc Diabetol,15,139.
  49. Scirica, BM,Bhatt, DL,Braunwald, E(2013).Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.N Engl J Med,369,1317-1326.
  50. Vaccaro, O,Masulli, M,Nicolucci, A(2017).Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.Lancet Diabetes Endocrinol,5,887-897.
  51. Vetrone, LM,Zaccardi, F,Webb, DR(2019).Cardiovascular and mortality events in type 2 diabetes cardiovascular outcomes trials: a systematic review with trend analysis.Acta Diabetol,56,331-339.
  52. Watts, NB,Bilezikian, JP,Usiskin, K(2016).Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus.J Clin Endocrinol Metab,101,157-166.
  53. Wiviott, SD,Raz, I,Bonaca, MP(2019).Dapagliflozin and cardiovascular outcomes in type 2 diabetes.N Engl J Med,380,347-357.
  54. Yang, SJ,Min, KW,Gupta, SK(2013).Yang SJA multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.Diabetes Obes Metab,15,410-416.
  55. Zannad, F,Cannon, CP,Cushman, WC(2015).Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.Lancet,385,2067-2076.
  56. Zelniker, TA,Wiviott, SD,Raz, I(2019).SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.Lancet,393,31-39.
  57. Zinman, B,Inzucchi, SE,Lachin, JM(2017).Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk.Stroke,48,1218-1225.
  58. Zinman, B,Wanner, C,Lachin, JM(2015).Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.N Engl J Med,373,2117-2128.
print cancel